Eight years after pivotal data were presented publicly supporting its use in first-line advanced ovarian cancer after surgery, Roche's VEGF inhibitor Avastin finally has been approved by the US FDA for this indication.
The June 13 approval covers treatment with Avastin (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as...






